Long-term (12-month) administration of fluticasone furoate 110 microg od revealed an AE profile typical of the intranasal corticosteroid class in both adult and adolescent patients with PAR, with no evidence of clinically relevant systemic corticosteroid exposure.

FF QD was well tolerated and demonstrated efficacy in children aged 2 to 11 years with PAR.

This study can impact local management of AOM, and it should encourage continuous surveillance of AOM microbiology in Chile and other developing countries.